Plasma-derived extracellular vesicles transfer microRNA-130a-3p to alleviate myocardial ischemia/reperfusion injury by targeting ATG16L1

Sato, Yu; Tang, Xuepei; Zheng, Tinghui; Li, Shuhao; Ren, Haibo; Wu, Hailong; Peng, Fei; Gong, Lianggeng

doi:10.1007/s00441-022-03605-0

Cited by 9 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the manual method, we identified a total of 29 highly differential miRNAs (|log2 fold change|>0.5 and p-value<0.05). Among these, 21 miRNAs displayed expression levels similar to those of Upon reviewing the relevant literature, we found that some of these differentially expressed miRNAs have known involvement in processes related to vascular formation, autophagy, and muscle differentiation [29][30][31][32][33][34][35][36]. The ERT improved the expression of most of these differential miRNAs toward the levels observed in the healthy group.…”

Section: Mirnas Expression Profiles With and Without Enzyme Replaceme...mentioning

confidence: 70%

Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations

Fang,

Ayyadurai,

Pybus

et al. 2024

Preprint

View full text Add to dashboard Cite

Fabry disease, an X-linked lysosomal storage disorder caused by galactosidase alpha (GLA) gene mutations, exhibits diverse clinical manifestations, and poses significant diagnostic challenges. Early diagnosis and treatment are crucial for improved patient outcomes, pressing the need for reliable biomarkers. In this study, we aimed to identify miRNA candidates as potential biomarkers for Fabry disease using the KingFisher™ automated isolation method and NanoString nCounter® miRNA detection assay. Clinical serum samples were collected from both healthy subjects and Fabry disease patients. RNA extraction from the samples was performed using the KingFisher™ automated isolation method with the MagMAX mirVanaTM kit or manually using the Qiagen miRNeasy kit. The subsequent NanoString nCounter® miRNA detection assay showed consistent performance and no correlation between RNA input concentration and raw count, ensuring reliable and reproducible results. Interestingly, the detection range and highly differential miRNA between the control and disease groups were found to be distinct depending on the isolation method employed. Nevertheless, enrichment analysis of miRNA-targeting genes consistently revealed significant associations with angiogenesis pathways in both isolation methods. Additionally, our investigation into the impact of enzyme replacement therapy on miRNA expression indicated that some differential miRNAs may be sensitive to treatment. Our study provides valuable insights to identify miRNA biomarkers for Fabry disease. While different isolation methods yielded various detection ranges and highly differential miRNAs, the consistent association with angiogenesis pathways suggests their significance in disease progression. These findings lay the groundwork for further investigations and validation studies, ultimately leading to the development of non-invasive and reliable biomarkers to aid in early diagnosis and treatment monitoring for Fabry disease.

show abstract

Section: Mirnas Expression Profiles With and Without Enzyme Replaceme...mentioning

confidence: 70%

Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations

Fang,

Ayyadurai,

Pybus

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Compared to free drugs, nanomedicine has better therapeutic effects and safety, attributed to its multifunctional carrier selection, targeted and controlled drug release, and improved bioavailability ( 160 ). Currently, common nanocarriers include liposomes ( 161 – 163 ), polymer nanoparticles ( 164 , 165 ), inorganic nanoparticles ( 166 ) and extracellular vesicles ( 167 – 169 ). Carvedilol, a nonselective β-blocker, was encapsulated into platelet membrane vesicles (PMVs).…”

Section: Discussionmentioning

confidence: 99%

A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023

Wang

Guo

Zhang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundMyocardial ischemia/reperfusion injury (MIRI) refers to the more severe damage that occurs in the previously ischemic myocardium after a short-term interruption of myocardial blood supply followed by restoration of blood flow within a certain period of time. MIRI has become a major challenge affecting the therapeutic efficacy of cardiovascular surgery.MethodsA scientific literature search on MIRI-related papers published from 2000 to 2023 in the Web of Science Core Collection database was conducted. VOSviewer was used for bibliometric analysis to understand the scientific development and research hotspots in this field.ResultsA total of 5,595 papers from 81 countries/regions, 3,840 research institutions, and 26,202 authors were included. China published the most papers, but the United States had the most significant influence. Harvard University was the leading research institution, and influential authors included Lefer David J., Hausenloy Derek J., Yellon Derek M., and others. All keywords can be divided into four different directions: risk factors, poor prognosis, mechanisms and cardioprotection.ConclusionResearch on MIRI is flourishing. It is necessary to conduct an in-depth investigation of the interaction between different mechanisms and multi-target therapy will be the focus and hotspot of MIRI research in the future.

show abstract

“…Other studies have shown that plasma exosomes produced by ischemic preconditioning have cardioprotective effects in rat HF models, protecting the heart in vivo 149 . In addition, plasma‐derived EVs containing miR‐130a‐3p reduced excessive autophagy and ameliorated myocardial I/R injury through miR‐130a‐3p, which targets and inhibits the autophagy‐related gene autophagy‐related 16 like 1 ( ATG16L1) in cardiomyocytes 150 . Moreover, the absence of lncRNA HLA complex group 15 ( HCG15 ) in the exosomes of MI patients prevented AMI via the NF‐κB/p65 and p38 pathways 151 …”

Section: Evs Derived From Different Cell Types Promote the Treatment ...mentioning

confidence: 98%

“…149 In addition, plasma-derived EVs containing miR-130a-3p reduced excessive autophagy and ameliorated myocardial I/R injury through miR-130a-3p, which targets and inhibits the autophagy-related gene autophagy-related 16 like 1 (ATG16L1) in cardiomyocytes. 150 Moreover, the absence of lncRNA HLA complex group 15 (HCG15) in the exosomes of MI patients prevented AMI via the NF-κB/p65 and p38 pathways. 151 The role of programmed necrosis in I/R injury is critical.…”

Section: Evs From Plasmamentioning

confidence: 99%

Mechanisms and therapeutic strategies of extracellular vesicles in cardiovascular diseases

Li,

Feng,

Zhou

et al. 2023

MedComm

View full text Add to dashboard Cite

Cardiovascular disease (CVD) significantly impacts global society since it is the leading cause of death and disability worldwide, and extracellular vesicle (EV)‐based therapies have been extensively investigated. EV delivery is involved in mediating the progression of CVDs and has great potential to be biomarker and therapeutic molecular carrier. Besides, EVs from stem cells and cardiac cells can effectively protect the heart from various pathologic conditions, and then serve as an alternative treatment for CVDs. Moreover, the research of using EVs as delivery carriers of therapeutic molecules, membrane engineering modification of EVs, or combining EVs with biomaterials further improves the application potential of EVs in clinical treatment. However, currently there are only a few articles summarizing the application of EVs in CVDs. This review provides an overview of the role of EVs in the pathogenesis and diagnosis of CVDs. It also focuses on how EVs promote the repair of myocardial injury and therapeutic methods of CVDs. In conclusion, it is of great significance to review the research on the application of EVs in the treatment of CVDs, which lays a foundation for further exploration of the role of EVs, and clarifies the prospect of EVs in the treatment of myocardial injury.

show abstract

Plasma-derived extracellular vesicles transfer microRNA-130a-3p to alleviate myocardial ischemia/reperfusion injury by targeting ATG16L1

Cited by 9 publications

References 53 publications

Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations

Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations

A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023

Mechanisms and therapeutic strategies of extracellular vesicles in cardiovascular diseases

Contact Info

Product

Resources

About